Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

How is New Innovation Giving a Much-Needed Boost to Women’s Health and Wellness? (Maddyness UK)

Related Content

Amgen Files BPCIA Complaints Against Dr. Reddy’s/Alvotech and Amneal Regarding Denosumab Biosimilars

Hikma Launches Ustekinumab Biosimilar STARJEMZA

Samsung Biologics Completes Spin-Off and Launches Samsung Epis Holdings

Prefilled Syringe Presentation of GSK’s SHINGRIX Receives Positive CHMP Opinion

Recent Biologics Decisions at Health Canada

Takeda and Innovent Biologics Enter Collaboration Agreement on IBI343 and IBI363 Cancer Drugs

FDA Grants Interchangeability Designation to Fresenius Kabi’s and Celltrion’s Denosumab Biosimilars

FDA Approves Genentech’s GAZYVA® (obinutuzumab)

State Drug Price Transparency Laws and Prescription Drug Affordability Boards – 2025 Year-End Review Webinar

Goodwin Advises SixPeaks Bio on Acquisition by AstraZeneca for Up to $300 Million

Vidi Capital Acquires the group CIL11

Goodwin Advises Braveheart Bio in $185 Million Series A Financing and License Agreement with Hengrui Pharma

Best Law Firms 2026 Names Goodwin ERISA Litigation Law Firm of the Year and Recognizes 50 Practice Areas

nextProtein Raises €18m in Series B Financing

Goodwin Represents Nanjing Leads Biolabs on Exclusive License Agreement with Dianthus Therapeutics for LBL-047 for Up to $1 Billion

IAM Global Leaders 2026 Recognizes Six Goodwin Partners

Life Sciences

Women’s Health and Wellness

Healthcare